Optiscan Imaging, a medical technology company, has signed a memorandum of understanding with the University of Minnesota College of Veterinary Medicine.
The collaboration aims to enhance cancer detection and treatment in animals using Optiscan's advanced digital confocal laser endomicroscopic imaging system.
The MOU outlines plans for a collaborative research agreement to develop clinical data for Optiscan's imaging system, initially focusing on cancer research in companion animals.
By leveraging Optiscan's real-time in vivo imaging technology and the university's veterinary expertise, the project aims to improve veterinary diagnostics and treatment.
Optiscan CEO and Managing Director Camile Farah, said, "The signing of this MOU with the prestigious University of Minnesota College of Veterinary Medicine is a fantastic result on multiple fronts."
"Combining the respective strengths of Optiscan and the University of Minnesota opens the way for the unlocking of new possibilities in the diagnosis and treatment of critical conditions of concern to veterinary medicine," Farah added.
The planned research will provide required clinical study data for the US Food and Drug Administration clearance of Optiscan’s imaging platform for use in veterinary medicine.
The agreement aligns with Optiscan's strategy to expand its addressable markets and enhance medical applications across various fields and jurisdictions.
The collaboration represents a significant step for Optiscan as it explores the extensive veterinary market, focusing on improved health outcomes for animals in the US and globally.
Optiscan looks forward to updating the market on the outcomes of this initiative and developing additional partnerships.